Rating Change
Wedbush reiterated its Outperform rating on Jade Biosciences, Inc. (NASDAQ:JBIO) on August 11, 2026.
reiterateNASDAQ:JBIO
Wedbush Reiterates Outperform Rating on Jade Biosciences, Inc. (JBIO)
Wedbush reiterated its Outperform rating on Jade Biosciences, Inc. (NASDAQ:JBIO) on August 11, 2026.
At publication ·
What changed
Jade Biosciences, Inc. (NASDAQ:JBIO) · reiterate
- Firm
- Wedbush
- Rating
- Outperform to Outperform
- Price at event
- $22.28
- Market capitalization
- $484.2M
At a glance
Key takeaways
- Wedbush reiterated an Outperform rating on Jade Biosciences (JBIO) on August 11, 2026, with the stock trading at $22.28 and a market capitalization of $484.2 million.
Market Context
Jade Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $22.28 with a market capitalization of $484.2M. The stock has gained 83.0% over the past 52 weeks.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Jade Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Jade Biosciences, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 11, 2026 | Wedbush | Outperform | N/A |
| Aug 10, 2026 | BTIG | Buy | N/A |
| Jun 15, 2026 | UBS | Buy | N/A |
| Jun 02, 2026 | Wedbush | Outperform | N/A |
| Jun 01, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View JBIO Stock Page
Frequently Asked Questions
What does the Outperform rating mean for JBIO?
A rating of Outperform from Wedbush reflects the analyst's outlook on Jade Biosciences, Inc. (NASDAQ:JBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the JBIO forecast page.